Filing Details

Accession Number:
0001764013-23-000006
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-01-13 08:13:29
Reporting Period:
2023-01-11
Accepted Time:
2023-01-13 08:13:29
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1764013 Immunovant Inc. IMVT Biological Products, (No Disgnostic Substances) (2836) 832771572
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1864280 L. William Macias C/O Immunovant, Inc.
320 W 37Th Street, 6Th Floor
New York NY 10018
Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2023-01-11 120 $15.11 307,981 No 4 S Direct
Common Stock Disposition 2023-01-11 44,448 $16.75 263,533 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
Footnotes
  1. On November 5, 2021, the holder was granted 112,108 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on November 9, 2021. These RSUs vested in their entirety on January 1, 2023. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of these RSUs and do not represent a discretionary sale by the holder.
  2. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.06 - $15.15 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
  3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.30 - $16.80 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.